Phosphoproteome Analysis Reveals Differential Mode of Action of Sorafenib in 
Wildtype and Mutated FLT3 Acute Myeloid Leukemia (AML) Cells

Roolf, Catrin; Dybowski, Nikolaj; Sekora, Anett; Mueller, Stefan; Knuebel, Gudrun; Tebbe, Andreas; Escobar, Hugo Murua; Godl, Klaus; Junghanss, Christian; Schaab, Christoph

doi:10.1074/mcp.M117.067462

Datensatz

DATENSATZ AKTIONENEXPORT

Zur Ablage hinzufügen

Lokale TagsFreigabegeschichteDetailsÜbersicht

Freigegeben

Zeitschriftenartikel

Phosphoproteome Analysis Reveals Differential Mode of Action of Sorafenib in Wildtype and Mutated FLT3 Acute Myeloid Leukemia (AML) Cells

MPG-Autoren

/persons/resource/persons78611

Schaab, Christoph
Cox, Jürgen / Computational Systems Biochemistry, Max Planck Institute of Biochemistry, Max Planck Society;

Externe Ressourcen

http://www.mcponline.org/cgi/content/full/M117.067462/DC1
(Ergänzendes Material)

Volltexte (beschränkter Zugriff)

Für Ihren IP-Bereich sind aktuell keine Volltexte freigegeben.

Volltexte (frei zugänglich)

Mol Cell Proteomics-2017-Roolf-1365-76.pdf
(Verlagsversion), 3MB

Ergänzendes Material (frei zugänglich)

Es sind keine frei zugänglichen Ergänzenden Materialien verfügbar

Zitation

Roolf, C., Dybowski, N., Sekora, A., Mueller, S., Knuebel, G., Tebbe, A., et al. (2017). Phosphoproteome Analysis Reveals Differential Mode of Action of Sorafenib in Wildtype and Mutated FLT3 Acute Myeloid Leukemia (AML) Cells. Molecular and Cellular Proteomics, 16(7), 1365-1376. doi:10.1074/mcp.M117.067462.

Zitierlink: https://hdl.handle.net/11858/00-001M-0000-002D-DBE8-C

Zusammenfassung

Constitutively activating internal tandem duplication (ITD) alterations of the receptor tyrosine kinase FLT3 (Fms-like tyrosine kinase 3) are common in acute myeloid leukemia (AML) and classifies FLT3 as an attractive therapeutic target. So far, applications of FLT3 small molecule inhibitors have been investigated primarily in FLT3-ITD+ patients. Only recently, a prolonged event-free survival has been observed in AML patients who were treated with the multikinase inhibitor sorafenib in addition to standard therapy. Here, we studied the sorafenib effect on proliferation in a panel of 13 FLT3-ITD- and FLT3-ITD+ AML cell lines. Sorafenib IC50 values ranged from 0.001 to 5.6 mu M, whereas FLT3-ITD-cells (MOLM-13, MV4-11) were found to be more sensitive to sorafenib than FLT3-ITD- cells. However, we identified two FLT3-ITD+ cell lines (MONO-MAC- 1 and OCI-AML-2) which were also sorafenib sensitive. Phosphoproteome analyses revealed that the affected pathways differed in sorafenib sensitive FLT3ITD(-) and FLT3-ITD+ cells. In MV4-11 cells sorafenib suppressed mTOR signaling by direct inhibition of FLT3. In MONO-MAC-1 cells sorafenib inhibited the MEK/ERK pathway. These data suggest that the FLT3 status in AML patients might not be the only factor predicting response to treatment with sorafenib.